Latest Pharma Insights
E.l.f. Invests $50M Tariff Refund Into Global Brand Push
E.l.f. Beauty posted its 30th consecutive quarter of net sales growth and raised its full-year outlook on the strength of rhode's record-breaking momentum, while unveiling plans to reinvest a $50m tariff refund into marketing and global expansion across its brand portfolio.
HBW Insight - August 6, 2026
E.l.f. Beauty posted its 30th consecutive quarter of net sales growth and raised its full-year outlook on the strength of rhode's record-breaking momentum, while unveiling plans to reinvest a $50m tariff refund into marketing and global expansion across its brand portfolio.
HBW Insight - August 6, 2026
Personalized Steps In Herbalife’s 5.4% Q2 Growth
Worldwide net sales grew to $1.3bn during April-June period but firm reports net loss of $26.3m due to retiring $94.6m in debt.
HBW Insight - August 6, 2026
Worldwide net sales grew to $1.3bn during April-June period but firm reports net loss of $26.3m due to retiring $94.6m in debt.
HBW Insight - August 6, 2026
Spending Bills Are US Battlefield Over Lawful Hemp
Latest congressional moves for and against extending effective date for lower THC limits are Senate amendments to House continuing resolution to keep federal agencies funded through Dec. 11 following end of FY 2026.
HBW Insight - August 6, 2026
Latest congressional moves for and against extending effective date for lower THC limits are Senate amendments to House continuing resolution to keep federal agencies funded through Dec. 11 following end of FY 2026.
HBW Insight - August 6, 2026
Asia Deal Watch: AstraZeneca Teams With CSPC On Biologics Manufacturing In China
Plus deals involving Alphamab/Pathos AI, Taisho/Kaigene, LTT Bio-Pharma/Apogepha, Sino Biopharmaceutical/PT Tempo, Nippon Shinyaku/Aquelys, Qilu/TYK and more.
Scrip - August 6, 2026
Plus deals involving Alphamab/Pathos AI, Taisho/Kaigene, LTT Bio-Pharma/Apogepha, Sino Biopharmaceutical/PT Tempo, Nippon Shinyaku/Aquelys, Qilu/TYK and more.
Scrip - August 6, 2026
Insmed Finds Itself In Rare Company: A SMID Cap With A Blockbuster Launch
Brinsupri is on track to generate $1.25bn-$1.4bn in its first full year on the market, something that is hard to accomplish, particularly outside of big pharma.
Scrip - August 6, 2026
Brinsupri is on track to generate $1.25bn-$1.4bn in its first full year on the market, something that is hard to accomplish, particularly outside of big pharma.
Scrip - August 6, 2026
Orzeyful Approval Gives Takeda First Of Three Much-Needed Growth Products
The US FDA approved the oral orexin receptor 2 agonist for narcolepsy type 1, with the psoriasis drug zasocitinib and the polycythemia vera drug rusfertide also awaiting FDA decisions.
Scrip - August 6, 2026
The US FDA approved the oral orexin receptor 2 agonist for narcolepsy type 1, with the psoriasis drug zasocitinib and the polycythemia vera drug rusfertide also awaiting FDA decisions.
Scrip - August 6, 2026
Early Signs Of The Oral Revolution In Immune-mediated Inflammatory Disease
Oral therapies are forecast to grow in the immune-mediated inflammatory disease market from $16.7bn in 2025 to $45.1bn in 2032, lifting their share to 25.5%. The oral promise rests on a handful of assets — above all AbbVie's Rinvoq, which holds much of the oral sales and loses exclusivity in 2033.
In Vivo - August 6, 2026
Oral therapies are forecast to grow in the immune-mediated inflammatory disease market from $16.7bn in 2025 to $45.1bn in 2032, lifting their share to 25.5%. The oral promise rests on a handful of assets — above all AbbVie's Rinvoq, which holds much of the oral sales and loses exclusivity in 2033.
In Vivo - August 6, 2026
Polen Touts ‘New BD,’ Product Innovation As Company Raises 2026 Earnings Outlook
BD reported a strong third quarter, saying its first full quarter as the “New BD” exceeded expectations. The company raised its full-year guidance citing momentum in GLP-1 drug delivery, advanced patient monitoring, PureWick and advanced tissue regeneration, and highlighted several product launches.
Medtech Insight - August 6, 2026
BD reported a strong third quarter, saying its first full quarter as the “New BD” exceeded expectations. The company raised its full-year guidance citing momentum in GLP-1 drug delivery, advanced patient monitoring, PureWick and advanced tissue regeneration, and highlighted several product launches.
Medtech Insight - August 6, 2026
Solventum Eyes Spin Or Sale Of Health IT Unit As 3M Split Nears End, Raises Full-Year Guidance
Solventum will separate from its $1.4bn Health Information Systems unit via spin-off, sale or merger, leaving a MedSurg-and-dental medtech company as its 3M split ends. A Q2 beat and Acera's strong start fed a full guidance raise.
Medtech Insight - August 6, 2026
Solventum will separate from its $1.4bn Health Information Systems unit via spin-off, sale or merger, leaving a MedSurg-and-dental medtech company as its 3M split ends. A Q2 beat and Acera's strong start fed a full guidance raise.
Medtech Insight - August 6, 2026
AI Used By More Than Half Of Younger French Health Consumers
More than a quarter of French adults now consult an AI tool such as ChatGPT when they have a minor health problem, rising to more than half of under-35s, according to NèreS.
HBW Insight - August 6, 2026
More than a quarter of French adults now consult an AI tool such as ChatGPT when they have a minor health problem, rising to more than half of under-35s, according to NèreS.
HBW Insight - August 6, 2026
Digital Health Roundup: CE Mark For Vision-Restoring Implant, AI Chatbot Rules, MS Deal
Science Corp.'s PRIMA brain-computer interface receives CE mark for restoring central vision in AMD patients. Viz.ai partners with Cortechs.ai on MS tracking. AMA urges Congress to regulate mental health AI chatbots. MedLink earns Mayo Clinic Platform qualification.
Medtech Insight - August 6, 2026
Science Corp.'s PRIMA brain-computer interface receives CE mark for restoring central vision in AMD patients. Viz.ai partners with Cortechs.ai on MS tracking. AMA urges Congress to regulate mental health AI chatbots. MedLink earns Mayo Clinic Platform qualification.
Medtech Insight - August 6, 2026
Merck KGaA Bets On Rare Diseases And Life Science To Drive Growth
Merck KGaA lifted its full-year net sales forecast to €21.0bn–€21.8bn, with rare disease drugs Ogsiveo and Gomekli generating €207m in combined first-half sales as the strategic pivot gathers pace.
Scrip - August 6, 2026
Merck KGaA lifted its full-year net sales forecast to €21.0bn–€21.8bn, with rare disease drugs Ogsiveo and Gomekli generating €207m in combined first-half sales as the strategic pivot gathers pace.
Scrip - August 6, 2026
Adalvo And Richter Expand GLP-1s Deal With Tirzepatide Rivals To Zepbound And Mounjaro
After last year striking a deal on semaglutide, Adalvo and Gedeon Richter have expanded their GLP-1 alliance to also encompass tirzepatide rivals to Mounjaro and Zepbound – backed by two ANDA filings that have already been submitted to the US FDA.
Generics Bulletin - August 6, 2026
After last year striking a deal on semaglutide, Adalvo and Gedeon Richter have expanded their GLP-1 alliance to also encompass tirzepatide rivals to Mounjaro and Zepbound – backed by two ANDA filings that have already been submitted to the US FDA.
Generics Bulletin - August 6, 2026
LifeMine’s Plans Mushroom With Capital Raise For Phase II Organ Transplant Study
The company will take its fungus-derived drug, designed to address the toxicity of calcineurin inhibitors, into Phase II development in early 2027.
Scrip - August 6, 2026
The company will take its fungus-derived drug, designed to address the toxicity of calcineurin inhibitors, into Phase II development in early 2027.
Scrip - August 6, 2026
Deals Shaping The Medtech And Diagnostics Industries, July 2026
An interactive look at medtech and diagnostics deals made during July 2026. Data courtesy of Biomedtracker.
Medtech Insight - August 6, 2026
An interactive look at medtech and diagnostics deals made during July 2026. Data courtesy of Biomedtracker.
Medtech Insight - August 6, 2026
Execs On The Move: July 27–31, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - August 6, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - August 6, 2026
Phase III Data Stoke Arrowhead’s Rivalry With Ionis
Competition is fierce between Ionis and Arrowhead in the emerging severe hypertriglyceridemia market, with Phase III readouts, price slashing and patent battles all in the mix. Arrowhead’s CEO talks to Scrip about why he thinks new data give his firm an advantage.
Scrip - August 6, 2026
Competition is fierce between Ionis and Arrowhead in the emerging severe hypertriglyceridemia market, with Phase III readouts, price slashing and patent battles all in the mix. Arrowhead’s CEO talks to Scrip about why he thinks new data give his firm an advantage.
Scrip - August 6, 2026
Leqembi Joins Kisunla In India But Ecosystem Gaps Cloud Market Promise
Eisai’s Leqembi makes debut alongside Lilly’s Kisunla in India, a market with close 9 million people living with dementia, but ecosystem gaps threaten early adoption. Pricing innovation could be pivotal to drive access.
Scrip - August 6, 2026
Eisai’s Leqembi makes debut alongside Lilly’s Kisunla in India, a market with close 9 million people living with dementia, but ecosystem gaps threaten early adoption. Pricing innovation could be pivotal to drive access.
Scrip - August 6, 2026
Spain’s Top Online Supplements Brand Targets European Leadership
Spain's number-one digital-native supplements player Aldous Bio has secured investment for European expansion from Nazca Capital.
HBW Insight - August 6, 2026
Spain's number-one digital-native supplements player Aldous Bio has secured investment for European expansion from Nazca Capital.
HBW Insight - August 6, 2026
Sandoz Earns ‘Blue Chip’ Status With Biosimilars Growth And GLP-1 Opportunity
Sandoz says it has earned its “blue chip” status after a first half that saw biosimilars sales continue to boom, with further pipeline expansion through the addition of four products – as well as key regulatory developments that set up its ability to take advantage of the generic GLP-1 opportunity.
Generics Bulletin - August 6, 2026
Sandoz says it has earned its “blue chip” status after a first half that saw biosimilars sales continue to boom, with further pipeline expansion through the addition of four products – as well as key regulatory developments that set up its ability to take advantage of the generic GLP-1 opportunity.
Generics Bulletin - August 6, 2026
CGPA Accentuates The Positive After Canadian Supreme Court Patent Ruling
Canada’s off-patent industry association the CGPA says there are positive takeaways from a recent Supreme Court decision that saw Pharmascience kept out of the market for its generic version of Janssen’s Invega Sustenna.
Generics Bulletin - August 6, 2026
Canada’s off-patent industry association the CGPA says there are positive takeaways from a recent Supreme Court decision that saw Pharmascience kept out of the market for its generic version of Janssen’s Invega Sustenna.
Generics Bulletin - August 6, 2026
Eylea High-Dose Biosimilars Emerge As Next Competitive Battleground
Amgen is advancing an 8mg Eylea HD biosimilar into Phase III as Pavblu sales surge, as new aflibercept rivals enter the US market and biosimilar competition erodes its denosumab franchise.
Generics Bulletin - August 6, 2026
Amgen is advancing an 8mg Eylea HD biosimilar into Phase III as Pavblu sales surge, as new aflibercept rivals enter the US market and biosimilar competition erodes its denosumab franchise.
Generics Bulletin - August 6, 2026
Will AI Help Or Hinder Electronic Health Records?
Only 20% of EHR data is structured. AI can make that data usable, but human expertise remains central.
Medtech Insight - August 6, 2026
Only 20% of EHR data is structured. AI can make that data usable, but human expertise remains central.
Medtech Insight - August 6, 2026
Jazz Maps Out Oncology Growth Path With Zanidatamab PDUFA, Zepzelca Label Update
Beyond a strong quarter, Jazz used its latest update to map out an oncology portfolio approaching several key regulatory, clinical and commercial milestones.
Scrip - August 6, 2026
Beyond a strong quarter, Jazz used its latest update to map out an oncology portfolio approaching several key regulatory, clinical and commercial milestones.
Scrip - August 6, 2026
Moderna’s Flu Vaccine Approval Fuels Hopes For COVID-Influenza Shot
Moderna has gained US FDA approval for the first mRNA-based influenza vaccine, raising hopes that the nod sets it up for a refiling of a combo COVID-19/flu vaccine that it withdrew last year.
Scrip - August 6, 2026
Moderna has gained US FDA approval for the first mRNA-based influenza vaccine, raising hopes that the nod sets it up for a refiling of a combo COVID-19/flu vaccine that it withdrew last year.
Scrip - August 6, 2026
Different Strokes: Strides And OneSource Spell Out Approaches To Iran War, Tariffs
Dissimilar business models and customer mix mean Strides Pharma and its spin-off CDMO OneSource Specialty are taking divergent paths through the same headwinds of the Iran war-led disruption and Trump's threatened tariffs on generic drugs.
Scrip - August 6, 2026
Dissimilar business models and customer mix mean Strides Pharma and its spin-off CDMO OneSource Specialty are taking divergent paths through the same headwinds of the Iran war-led disruption and Trump's threatened tariffs on generic drugs.
Scrip - August 6, 2026
Get To Know: Gut Health Specialist PrecisionBiotics
Exclusive: Novonesis subsidiary PrecisionBiotics tells HBW Insight why the shift towards prevention and self-care is opening up the European gut health market.
HBW Insight - August 6, 2026
Exclusive: Novonesis subsidiary PrecisionBiotics tells HBW Insight why the shift towards prevention and self-care is opening up the European gut health market.
HBW Insight - August 6, 2026
‘It’s Important That We Evolve’ – IGBA’s Gaunt On Being The Voice Of The Global Off-Patent Industry
Ana Gaunt recently took over as secretary general of the IGBA. In this interview she sets out her four key priority areas, while also revealing future initiatives – including a value-based report as well as refocusing certain IGBA activities to give member associations a stronger voice.
In Vivo - August 6, 2026
Ana Gaunt recently took over as secretary general of the IGBA. In this interview she sets out her four key priority areas, while also revealing future initiatives – including a value-based report as well as refocusing certain IGBA activities to give member associations a stronger voice.
In Vivo - August 6, 2026
The Medtech Rebound That Wasn’t: Strip Out AI Drug Discovery And H1 2026 Funding Hit A Six-Year Low
Medtech financing looked like it rebounded in H1 2026 — but the money went to AI drug discovery, not devices. Strip out biotech and pure medtech funding fell to $3.54bn, a six-year low, as venture collapsed, mega-rounds vanished and the IPO window stayed shut.
Medtech Insight - August 6, 2026
Medtech financing looked like it rebounded in H1 2026 — but the money went to AI drug discovery, not devices. Strip out biotech and pure medtech funding fell to $3.54bn, a six-year low, as venture collapsed, mega-rounds vanished and the IPO window stayed shut.
Medtech Insight - August 6, 2026
IFF Maps Growth Strategy Around Three Core Businesses
IFF said its portfolio transformation is positioning the company for faster growth and higher margins as it sharpens its focus on Taste, Scent and Health & Biosciences.
HBW Insight - August 6, 2026
IFF said its portfolio transformation is positioning the company for faster growth and higher margins as it sharpens its focus on Taste, Scent and Health & Biosciences.
HBW Insight - August 6, 2026
Asia Deal Watch: AstraZeneca Teams With CSPC On Biologics Manufacturing In China
Plus deals involving Alphamab/Pathos AI, Taisho/Kaigene, LTT Bio-Pharma/Apogepha, Sino Biopharmaceutical/PT Tempo, Nippon Shinyaku/Aquelys, Qilu/TYK and more.
Scrip - August 6, 2026
Plus deals involving Alphamab/Pathos AI, Taisho/Kaigene, LTT Bio-Pharma/Apogepha, Sino Biopharmaceutical/PT Tempo, Nippon Shinyaku/Aquelys, Qilu/TYK and more.
Scrip - August 6, 2026
Insmed Finds Itself In Rare Company: A SMID Cap With A Blockbuster Launch
Brinsupri is on track to generate $1.25bn-$1.4bn in its first full year on the market, something that is hard to accomplish, particularly outside of big pharma.
Scrip - August 6, 2026
Brinsupri is on track to generate $1.25bn-$1.4bn in its first full year on the market, something that is hard to accomplish, particularly outside of big pharma.
Scrip - August 6, 2026
Orzeyful Approval Gives Takeda First Of Three Much-Needed Growth Products
The US FDA approved the oral orexin receptor 2 agonist for narcolepsy type 1, with the psoriasis drug zasocitinib and the polycythemia vera drug rusfertide also awaiting FDA decisions.
Scrip - August 6, 2026
The US FDA approved the oral orexin receptor 2 agonist for narcolepsy type 1, with the psoriasis drug zasocitinib and the polycythemia vera drug rusfertide also awaiting FDA decisions.
Scrip - August 6, 2026
Merck KGaA Bets On Rare Diseases And Life Science To Drive Growth
Merck KGaA lifted its full-year net sales forecast to €21.0bn–€21.8bn, with rare disease drugs Ogsiveo and Gomekli generating €207m in combined first-half sales as the strategic pivot gathers pace.
Scrip - August 6, 2026
Merck KGaA lifted its full-year net sales forecast to €21.0bn–€21.8bn, with rare disease drugs Ogsiveo and Gomekli generating €207m in combined first-half sales as the strategic pivot gathers pace.
Scrip - August 6, 2026
LifeMine’s Plans Mushroom With Capital Raise For Phase II Organ Transplant Study
The company will take its fungus-derived drug, designed to address the toxicity of calcineurin inhibitors, into Phase II development in early 2027.
Scrip - August 6, 2026
The company will take its fungus-derived drug, designed to address the toxicity of calcineurin inhibitors, into Phase II development in early 2027.
Scrip - August 6, 2026
Phase III Data Stoke Arrowhead’s Rivalry With Ionis
Competition is fierce between Ionis and Arrowhead in the emerging severe hypertriglyceridemia market, with Phase III readouts, price slashing and patent battles all in the mix. Arrowhead’s CEO talks to Scrip about why he thinks new data give his firm an advantage.
Scrip - August 6, 2026
Competition is fierce between Ionis and Arrowhead in the emerging severe hypertriglyceridemia market, with Phase III readouts, price slashing and patent battles all in the mix. Arrowhead’s CEO talks to Scrip about why he thinks new data give his firm an advantage.
Scrip - August 6, 2026
Leqembi Joins Kisunla In India But Ecosystem Gaps Cloud Market Promise
Eisai’s Leqembi makes debut alongside Lilly’s Kisunla in India, a market with close 9 million people living with dementia, but ecosystem gaps threaten early adoption. Pricing innovation could be pivotal to drive access.
Scrip - August 6, 2026
Eisai’s Leqembi makes debut alongside Lilly’s Kisunla in India, a market with close 9 million people living with dementia, but ecosystem gaps threaten early adoption. Pricing innovation could be pivotal to drive access.
Scrip - August 6, 2026
Jazz Maps Out Oncology Growth Path With Zanidatamab PDUFA, Zepzelca Label Update
Beyond a strong quarter, Jazz used its latest update to map out an oncology portfolio approaching several key regulatory, clinical and commercial milestones.
Scrip - August 6, 2026
Beyond a strong quarter, Jazz used its latest update to map out an oncology portfolio approaching several key regulatory, clinical and commercial milestones.
Scrip - August 6, 2026
Moderna’s Flu Vaccine Approval Fuels Hopes For COVID-Influenza Shot
Moderna has gained US FDA approval for the first mRNA-based influenza vaccine, raising hopes that the nod sets it up for a refiling of a combo COVID-19/flu vaccine that it withdrew last year.
Scrip - August 6, 2026
Moderna has gained US FDA approval for the first mRNA-based influenza vaccine, raising hopes that the nod sets it up for a refiling of a combo COVID-19/flu vaccine that it withdrew last year.
Scrip - August 6, 2026
Different Strokes: Strides And OneSource Spell Out Approaches To Iran War, Tariffs
Dissimilar business models and customer mix mean Strides Pharma and its spin-off CDMO OneSource Specialty are taking divergent paths through the same headwinds of the Iran war-led disruption and Trump's threatened tariffs on generic drugs.
Scrip - August 6, 2026
Dissimilar business models and customer mix mean Strides Pharma and its spin-off CDMO OneSource Specialty are taking divergent paths through the same headwinds of the Iran war-led disruption and Trump's threatened tariffs on generic drugs.
Scrip - August 6, 2026
Polen Touts ‘New BD,’ Product Innovation As Company Raises 2026 Earnings Outlook
BD reported a strong third quarter, saying its first full quarter as the “New BD” exceeded expectations. The company raised its full-year guidance citing momentum in GLP-1 drug delivery, advanced patient monitoring, PureWick and advanced tissue regeneration, and highlighted several product launches.
Medtech Insight - August 6, 2026
BD reported a strong third quarter, saying its first full quarter as the “New BD” exceeded expectations. The company raised its full-year guidance citing momentum in GLP-1 drug delivery, advanced patient monitoring, PureWick and advanced tissue regeneration, and highlighted several product launches.
Medtech Insight - August 6, 2026
Solventum Eyes Spin Or Sale Of Health IT Unit As 3M Split Nears End, Raises Full-Year Guidance
Solventum will separate from its $1.4bn Health Information Systems unit via spin-off, sale or merger, leaving a MedSurg-and-dental medtech company as its 3M split ends. A Q2 beat and Acera's strong start fed a full guidance raise.
Medtech Insight - August 6, 2026
Solventum will separate from its $1.4bn Health Information Systems unit via spin-off, sale or merger, leaving a MedSurg-and-dental medtech company as its 3M split ends. A Q2 beat and Acera's strong start fed a full guidance raise.
Medtech Insight - August 6, 2026
Digital Health Roundup: CE Mark For Vision-Restoring Implant, AI Chatbot Rules, MS Deal
Science Corp.'s PRIMA brain-computer interface receives CE mark for restoring central vision in AMD patients. Viz.ai partners with Cortechs.ai on MS tracking. AMA urges Congress to regulate mental health AI chatbots. MedLink earns Mayo Clinic Platform qualification.
Medtech Insight - August 6, 2026
Science Corp.'s PRIMA brain-computer interface receives CE mark for restoring central vision in AMD patients. Viz.ai partners with Cortechs.ai on MS tracking. AMA urges Congress to regulate mental health AI chatbots. MedLink earns Mayo Clinic Platform qualification.
Medtech Insight - August 6, 2026
Deals Shaping The Medtech And Diagnostics Industries, July 2026
An interactive look at medtech and diagnostics deals made during July 2026. Data courtesy of Biomedtracker.
Medtech Insight - August 6, 2026
An interactive look at medtech and diagnostics deals made during July 2026. Data courtesy of Biomedtracker.
Medtech Insight - August 6, 2026
Execs On The Move: July 27–31, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - August 6, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - August 6, 2026
Will AI Help Or Hinder Electronic Health Records?
Only 20% of EHR data is structured. AI can make that data usable, but human expertise remains central.
Medtech Insight - August 6, 2026
Only 20% of EHR data is structured. AI can make that data usable, but human expertise remains central.
Medtech Insight - August 6, 2026
The Medtech Rebound That Wasn’t: Strip Out AI Drug Discovery And H1 2026 Funding Hit A Six-Year Low
Medtech financing looked like it rebounded in H1 2026 — but the money went to AI drug discovery, not devices. Strip out biotech and pure medtech funding fell to $3.54bn, a six-year low, as venture collapsed, mega-rounds vanished and the IPO window stayed shut.
Medtech Insight - August 6, 2026
Medtech financing looked like it rebounded in H1 2026 — but the money went to AI drug discovery, not devices. Strip out biotech and pure medtech funding fell to $3.54bn, a six-year low, as venture collapsed, mega-rounds vanished and the IPO window stayed shut.
Medtech Insight - August 6, 2026
E.l.f. Invests $50M Tariff Refund Into Global Brand Push
E.l.f. Beauty posted its 30th consecutive quarter of net sales growth and raised its full-year outlook on the strength of rhode's record-breaking momentum, while unveiling plans to reinvest a $50m tariff refund into marketing and global expansion across its brand portfolio.
HBW Insight - August 6, 2026
E.l.f. Beauty posted its 30th consecutive quarter of net sales growth and raised its full-year outlook on the strength of rhode's record-breaking momentum, while unveiling plans to reinvest a $50m tariff refund into marketing and global expansion across its brand portfolio.
HBW Insight - August 6, 2026
Personalized Steps In Herbalife’s 5.4% Q2 Growth
Worldwide net sales grew to $1.3bn during April-June period but firm reports net loss of $26.3m due to retiring $94.6m in debt.
HBW Insight - August 6, 2026
Worldwide net sales grew to $1.3bn during April-June period but firm reports net loss of $26.3m due to retiring $94.6m in debt.
HBW Insight - August 6, 2026
Spending Bills Are US Battlefield Over Lawful Hemp
Latest congressional moves for and against extending effective date for lower THC limits are Senate amendments to House continuing resolution to keep federal agencies funded through Dec. 11 following end of FY 2026.
HBW Insight - August 6, 2026
Latest congressional moves for and against extending effective date for lower THC limits are Senate amendments to House continuing resolution to keep federal agencies funded through Dec. 11 following end of FY 2026.
HBW Insight - August 6, 2026
AI Used By More Than Half Of Younger French Health Consumers
More than a quarter of French adults now consult an AI tool such as ChatGPT when they have a minor health problem, rising to more than half of under-35s, according to NèreS.
HBW Insight - August 6, 2026
More than a quarter of French adults now consult an AI tool such as ChatGPT when they have a minor health problem, rising to more than half of under-35s, according to NèreS.
HBW Insight - August 6, 2026
Spain’s Top Online Supplements Brand Targets European Leadership
Spain's number-one digital-native supplements player Aldous Bio has secured investment for European expansion from Nazca Capital.
HBW Insight - August 6, 2026
Spain's number-one digital-native supplements player Aldous Bio has secured investment for European expansion from Nazca Capital.
HBW Insight - August 6, 2026
Get To Know: Gut Health Specialist PrecisionBiotics
Exclusive: Novonesis subsidiary PrecisionBiotics tells HBW Insight why the shift towards prevention and self-care is opening up the European gut health market.
HBW Insight - August 6, 2026
Exclusive: Novonesis subsidiary PrecisionBiotics tells HBW Insight why the shift towards prevention and self-care is opening up the European gut health market.
HBW Insight - August 6, 2026
IFF Maps Growth Strategy Around Three Core Businesses
IFF said its portfolio transformation is positioning the company for faster growth and higher margins as it sharpens its focus on Taste, Scent and Health & Biosciences.
HBW Insight - August 6, 2026
IFF said its portfolio transformation is positioning the company for faster growth and higher margins as it sharpens its focus on Taste, Scent and Health & Biosciences.
HBW Insight - August 6, 2026
Adalvo And Richter Expand GLP-1s Deal With Tirzepatide Rivals To Zepbound And Mounjaro
After last year striking a deal on semaglutide, Adalvo and Gedeon Richter have expanded their GLP-1 alliance to also encompass tirzepatide rivals to Mounjaro and Zepbound – backed by two ANDA filings that have already been submitted to the US FDA.
Generics Bulletin - August 6, 2026
After last year striking a deal on semaglutide, Adalvo and Gedeon Richter have expanded their GLP-1 alliance to also encompass tirzepatide rivals to Mounjaro and Zepbound – backed by two ANDA filings that have already been submitted to the US FDA.
Generics Bulletin - August 6, 2026
Sandoz Earns ‘Blue Chip’ Status With Biosimilars Growth And GLP-1 Opportunity
Sandoz says it has earned its “blue chip” status after a first half that saw biosimilars sales continue to boom, with further pipeline expansion through the addition of four products – as well as key regulatory developments that set up its ability to take advantage of the generic GLP-1 opportunity.
Generics Bulletin - August 6, 2026
Sandoz says it has earned its “blue chip” status after a first half that saw biosimilars sales continue to boom, with further pipeline expansion through the addition of four products – as well as key regulatory developments that set up its ability to take advantage of the generic GLP-1 opportunity.
Generics Bulletin - August 6, 2026
CGPA Accentuates The Positive After Canadian Supreme Court Patent Ruling
Canada’s off-patent industry association the CGPA says there are positive takeaways from a recent Supreme Court decision that saw Pharmascience kept out of the market for its generic version of Janssen’s Invega Sustenna.
Generics Bulletin - August 6, 2026
Canada’s off-patent industry association the CGPA says there are positive takeaways from a recent Supreme Court decision that saw Pharmascience kept out of the market for its generic version of Janssen’s Invega Sustenna.
Generics Bulletin - August 6, 2026
Eylea High-Dose Biosimilars Emerge As Next Competitive Battleground
Amgen is advancing an 8mg Eylea HD biosimilar into Phase III as Pavblu sales surge, as new aflibercept rivals enter the US market and biosimilar competition erodes its denosumab franchise.
Generics Bulletin - August 6, 2026
Amgen is advancing an 8mg Eylea HD biosimilar into Phase III as Pavblu sales surge, as new aflibercept rivals enter the US market and biosimilar competition erodes its denosumab franchise.
Generics Bulletin - August 6, 2026
Early Signs Of The Oral Revolution In Immune-mediated Inflammatory Disease
Oral therapies are forecast to grow in the immune-mediated inflammatory disease market from $16.7bn in 2025 to $45.1bn in 2032, lifting their share to 25.5%. The oral promise rests on a handful of assets — above all AbbVie's Rinvoq, which holds much of the oral sales and loses exclusivity in 2033.
In Vivo - August 6, 2026
Oral therapies are forecast to grow in the immune-mediated inflammatory disease market from $16.7bn in 2025 to $45.1bn in 2032, lifting their share to 25.5%. The oral promise rests on a handful of assets — above all AbbVie's Rinvoq, which holds much of the oral sales and loses exclusivity in 2033.
In Vivo - August 6, 2026
‘It’s Important That We Evolve’ – IGBA’s Gaunt On Being The Voice Of The Global Off-Patent Industry
Ana Gaunt recently took over as secretary general of the IGBA. In this interview she sets out her four key priority areas, while also revealing future initiatives – including a value-based report as well as refocusing certain IGBA activities to give member associations a stronger voice.
In Vivo - August 6, 2026
Ana Gaunt recently took over as secretary general of the IGBA. In this interview she sets out her four key priority areas, while also revealing future initiatives – including a value-based report as well as refocusing certain IGBA activities to give member associations a stronger voice.
In Vivo - August 6, 2026